Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0779
    -0.0014 (-0.13%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0000 (-0.00%)
     
  • USD/JPY

    151.3030
    -0.0690 (-0.05%)
     
  • Bitcoin USD

    70,428.00
    +812.84 (+1.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,344.87
    +176.80 (+0.44%)
     

Biogen's blood disorder drug succeeds in late-stage trial

April 10 (Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial.

The drug, Eloctate, was being developed as a treatment for haemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a particular protein.

(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

Advertisement